Orion Oyj (ORNBV.HE) Stock Price
Orion Oyj Price
Revenue has compounded at 10.0% per year over the past 19 years to 1.89 B EUR. Earnings per share have grown at 11.2% per year over the last 19 years. Orion Oyj's net margin stands at 26.5%, up from 18.6% several years earlier. Orion Oyj currently offers a dividend yield of about 1.95%. The payout ratio is around 46% of earnings. The dividend has grown at 2.8% per year over the past 18 years. Analysts set a median price target of 76.50 EUR, implying 8.8% below the current price. Of 15 analysts, 11 rate the stock a buy — an overall Buy consensus.
Orion Oyj stock price
Orion Oyj business model & stock analysis
Frequently asked questions about Orion Oyj
The business model of Orion Oyj revolves around the development, manufacturing, and marketing of pharmaceuticals and diagnostic tests. Orion Oyj specializes in various therapeutic areas including neurological disorders, respiratory diseases, and oncology. They focus on research and development of new innovative drugs to address unmet medical needs. By combining expertise in pharmaceuticals and diagnostics, Orion Oyj aims to provide effective and safe treatment options for patients globally. With its strong commitment to scientific excellence and continuous innovation, Orion Oyj strives to improve the quality of life for individuals affected by various diseases.
Orion Oyj is primarily active in the pharmaceutical industry. As a leading Finnish pharmaceutical company, Orion Oyj specializes in the development, manufacturing, and marketing of innovative pharmaceuticals and active pharmaceutical ingredients. With a strategic focus on neurological and respiratory diseases, Orion Oyj aims to improve people's well-being and contribute to medical advancements. Not only does Orion Oyj offer a diverse range of products in these therapeutic areas, but it also operates globally, exporting its pharmaceuticals to numerous countries. This commitment to the pharmaceutical industry makes Orion Oyj a key player in the healthcare sector.
The main competitors of Orion Oyj in the market include Novartis AG, Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc.
Orion Oyj is a renowned Finnish pharmaceutical company. Founded in 1917, Orion has a rich history of over a century in the industry. The company focuses on developing innovative pharmaceuticals and diagnostic tests, ensuring the well-being of individuals globally. Throughout its existence, Orion Oyj has grown to become one of the leading pharmaceutical companies in Northern Europe, with a strong emphasis on research and development. With a diverse product portfolio that includes prescription medicines, generic drugs, and active pharmaceutical ingredients, Orion Oyj aims to improve people's lives and provide effective healthcare solutions.
Orion Oyj has achieved significant milestones throughout its history. The Finnish pharmaceutical company has successfully developed and launched various innovative drugs, contributing to advancements in healthcare. Notably, Orion Oyj achieved a major milestone with the development and commercialization of Stalevo, a medication for the treatment of Parkinson's disease. The company also made significant progress in the field of oncology with the launch of Simdax, a drug used to improve cardiac function in patients with acute decompensated heart failure. Additionally, Orion Oyj has expanded its global presence through strategic collaborations and acquisitions, further solidifying its position as a leading player in the pharmaceutical industry.
Orion Oyj is primarily present in Finland, where it is headquartered. As a Finnish pharmaceutical company, Orion Oyj operates mainly in the Nordic countries, including Sweden, Norway, Denmark, and Iceland. However, the company's reach extends beyond the Nordic region, with a presence in several other countries and regions worldwide. This includes markets in Europe, such as the United Kingdom, Germany, France, and Spain. Orion Oyj also has a global presence with its products being exported to numerous countries in Asia, Africa, the Americas, and Australia.
Orion Oyj represents a strong set of values and corporate philosophy. As a leading pharmaceutical company based in Finland, Orion Oyj is committed to improving people's well-being through the development and commercialization of innovative medicines and treatments. The company's core values include professionalism, reliability, and integrity. Orion Oyj aims to provide effective and safe healthcare solutions while maintaining a high ethical standard in all its operations. With a focus on research and development, Orion Oyj strives to contribute to medical advancements and enhance patient care worldwide. As a result, Orion Oyj maintains a strong reputation as a trustworthy and responsible pharmaceutical company.
Analysts currently set an average price target of 73.59 EUR for the Orion Oyj stock (median: 76.50 EUR), implying -12.3 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Orion Oyj stock: 11 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Orion Oyj to generate revenue of 2.10 B EUR and earnings per share of 4.03 EUR.
The Orion Oyj share (ORNBV.HE) is listed on 9 stock exchanges, including: London (0M2O.L), SIX (Zürich) (ORNBV.SW), Frankfurt (OFK.F), München (OFK.MU), Düsseldorf (OFK.DU).
Orion Oyj is a Finnish company that was founded in 1917 and is now considered a leading manufacturer of pharmaceuticals, diagnostics, and animal health products in Northern and Central Europe. The company is divided into three divisions: human pharmaceuticals, specialty pharmaceuticals, and animal health. The human pharmaceuticals division is the main source of revenue for the company and offers a wide range of prescription drugs for various therapy areas such as neurology, oncology, urology, gastroenterology, and cardiology. Orion Oyj continuously develops innovative products and technologies for the healthcare industry and has had numerous successful product launches in recent years. The specialty pharmaceuticals division specializes in manufacturing medications for rare diseases. Among other products, the company manufactures treatments for Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), and Parkinson's disease. The third business area is animal health. Orion Oyj offers a wide range of medications for livestock and pets. The company is a leader in the production of free-range pig vaccines, which are in high demand, particularly in Northern Europe and the Baltic states. Orion Oyj is headquartered in Espoo, Finland, and employs over 3,000 people worldwide. The company is also listed on the Finnish stock exchange and had a revenue of approximately 1.1 billion euros in 2019. Orion Oyj has a clear strategy regarding its products and services. It focuses on strong partnerships and investments in research and development as well as production. The company aims to strengthen its position as a market leader in Northern Europe and the specialized pharmaceutical industry worldwide. Additionally, Orion Oyj has a strong local presence in many European countries and operates production facilities in Finland and Germany. The high standards of product quality and production safety are supported by Orion Oyj's quality management system. As part of its international expansion, the company has also expanded into other markets, such as South America. In doing so, the company prioritizes sustainability and ethics. It aims to promote best practices in ecological, social, and community matters both within and outside the company. Overall, Orion Oyj is a company that offers a wide range of products and services in the field of human pharmaceuticals, specialty pharmaceuticals, and animal health. With its strong partnerships, investments in research and development, and a clear focus on the highest product quality and production safety, the company is well-equipped to expand its position as a leading provider in Northern Europe and the specialized pharmaceutical industry worldwide.
The expected revenue of Orion Oyj is 2.10 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Orion Oyj is 567.72 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Orion Oyj is currently 20.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Orion Oyj stock.
The price-to-sales ratio (P/S) of Orion Oyj is currently 5.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Orion Oyj stock.
The Eulerpool Quality Score for Orion Oyj is 8/10.
The ISIN of Orion Oyj is FI0009014377. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Orion Oyj is A0J3QM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Orion Oyj is ORNBV.HE. The ticker symbol is used to trade Orion Oyj shares on the stock exchange.
Orion Oyj stock
All fundamentals and in-depth analysis of Orion Oyj
Our stock analysis for Orion Oyj stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orion Oyj. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.